Literature DB >> 25953750

Management of pulmonary arterial hypertension.

Vallerie V McLaughlin1, Sanjiv J Shah2, Rogerio Souza3, Marc Humbert4.   

Abstract

Pulmonary hypertension (PH) is common and may result from a number of disorders, including left heart disease, lung disease, and chronic thromboembolic disease. Pulmonary arterial hypertension (PAH) is an uncommon disease characterized by progressive remodeling of the distal pulmonary arteries, resulting in elevated pulmonary vascular resistance and, eventually, in right ventricular failure. Over the past decades, knowledge of the basic pathobiology of PAH and its natural history, prognostic indicators, and therapeutic options has exploded. A thorough evaluation of a patient is critical to correctly characterize the PH. Cardiac studies, including echocardiography and right heart catheterization, are key elements in the assessment. Given the multitude of treatment options currently available for PAH, assessment of risk and response to therapy is critical in long-term management. This review also underscores unique situations, including perioperative management, intensive care unit management, and pregnancy, and highlights the importance of collaborative care of the PAH patient through a multidisciplinary approach.
Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  echocardiography; endothelin receptor antagonists; hemodynamics; phosphodiesterase type 5 inhibitors; prostacyclins; pulmonary arterial hypertension

Mesh:

Substances:

Year:  2015        PMID: 25953750     DOI: 10.1016/j.jacc.2015.03.540

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  90 in total

1.  Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model.

Authors:  Marius M Hoeper; Tilmann Kramer; Zixuan Pan; Christina A Eichstaedt; Jens Spiesshoefer; Nicola Benjamin; Karen M Olsson; Katrin Meyer; Carmine Dario Vizza; Anton Vonk-Noordegraaf; Oliver Distler; Christian Opitz; J Simon R Gibbs; Marion Delcroix; H Ardeschir Ghofrani; Doerte Huscher; David Pittrow; Stephan Rosenkranz; Ekkehard Grünig
Journal:  Eur Respir J       Date:  2017-08-03       Impact factor: 16.671

2.  Toward Precision Medicine in Pulmonary Arterial Hypertension.

Authors:  Eric D Austin; James E Loyd
Journal:  Am J Respir Crit Care Med       Date:  2015-12-01       Impact factor: 21.405

Review 3.  Discovery of a murine model of clinical PAH: Mission impossible?

Authors:  Zhiyu Dai; You-Yang Zhao
Journal:  Trends Cardiovasc Med       Date:  2016-12-15       Impact factor: 6.677

Review 4.  Neurohormonal modulation as therapeutic avenue for right ventricular dysfunction in pulmonary artery hypertension: till the dawn, waiting.

Authors:  Roy Emanuel; Astha Chichra; Nirav Patel; Thierry H Le Jemtel; Abhishek Jaiswal
Journal:  Ann Transl Med       Date:  2018-08

Review 5.  NADPH oxidase: its potential role in promotion of pulmonary arterial hypertension.

Authors:  Jing-Jie Peng; Bin Liu; Jin-Yun Xu; Jun Peng; Xiu-Ju Luo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-02-11       Impact factor: 3.000

6.  Evolving Schema for Employing Network Biology Approaches to Understand Pulmonary Hypertension.

Authors:  Shohini Ghosh-Choudhary; Stephen Y Chan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 7.  Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia.

Authors:  Dakota Gustafson; Jason E Fish; Jeffrey H Lipton; Nazanin Aghel
Journal:  Curr Hematol Malig Rep       Date:  2020-02       Impact factor: 3.952

8.  Intravenous treprostinil infusion via a fully implantable pump for pulmonary arterial hypertension.

Authors:  Ralf Ewert; Manuel J Richter; Regina Steringer-Mascherbauer; Ekkehard Grünig; Tobias J Lange; Christian F Opitz; Christian Warnke; Hossein-Ardeschir Ghofrani
Journal:  Clin Res Cardiol       Date:  2017-04-20       Impact factor: 5.460

9.  Pediatric Development of Bosentan Facilitated by Modeling and Simulation.

Authors:  Jochen Zisowsky; Martine Géhin; Andjela Kusic-Pajic; Andreas Krause; Maurice Beghetti; Jasper Dingemanse
Journal:  Paediatr Drugs       Date:  2017-04       Impact factor: 3.022

10.  Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report.

Authors:  John H Newman; Stuart Rich; Steven H Abman; John H Alexander; John Barnard; Gerald J Beck; Raymond L Benza; Todd M Bull; Stephen Y Chan; Hyung J Chun; Declan Doogan; Jocelyn Dupuis; Serpil C Erzurum; Robert P Frantz; Mark Geraci; Hunter Gillies; Mark Gladwin; Michael P Gray; Anna R Hemnes; Roy S Herbst; Adrian F Hernandez; Nicholas S Hill; Evelyn M Horn; Kendall Hunter; Zhi-Cheng Jing; Roger Johns; Sanjay Kaul; Steven M Kawut; Tim Lahm; Jane A Leopold; Greg D Lewis; Stephen C Mathai; Vallerie V McLaughlin; Evangelos D Michelakis; Steven D Nathan; William Nichols; Grier Page; Marlene Rabinovitch; Jonathan Rich; Franz Rischard; Sharon Rounds; Sanjiv J Shah; Victor F Tapson; Naomi Lowy; Norman Stockbridge; Gail Weinmann; Lei Xiao
Journal:  Am J Respir Crit Care Med       Date:  2017-06-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.